DEALS
Zhong Lun Advises Shenzhen Hepalink Pharmaceutical Co., Ltd. on SME Board IPO and Listing
Zhong Lun Advises Shenzhen Hepalink Pharmaceutical Co., Ltd. on SME Board IPO and Listing
On May 6, 2010, Shenzhen Hepalink Pharmaceutical Co., Ltd. was successfully listed on the Small and Medium Enterprise Board (SME Board) of the Shenzhen Stock Exchange Stock. The company finished its first day of trading at RMB175.17 per share, well up from its IPO price of RMB148, which was already the most expensive IPO valuation ever on the exchange.
Zhong Lun Law Firm advised the company on the IPO and listing. Partners Su Min, Xu Zhigang and Zou Xiaodong provided comprehensive legal services for the company.
Zhong Lun has provided legal services for the company for over 10 years. The company makes just one drug, a commonly used blood thinner called heparin, but the company has a huge advantage over competitors because it is the only Chinese company with approval from the US Food and Drug Administration to export finished heparin to the US.